康宁杰瑞制药-B（09966）于2026年11月11日发布公告称，当日于香港联交所场内回购股份23.9万股，占公司现有已发行股本约0.0248%。本次回购每股价格介乎6.045港元至6.195港元，合共耗资1,469,885港元（约146.99万港元）。
本次回购完成后，公司已发行股本由原先的965,393,697股减少至965,154,697股，同时库藏股数由8,988,000股增至9,227,000股，公司总股本仍为974,381,697股。董事会指出，该股份购回授权于2026年6月12日获股东大会批准，授权购回的股份总数为96,850,669股。截至目前，公司已根据该授权累计回购3,352,000股，占授权数量约0.3461%。公司并确认本次交易已遵守相关上市规则及适用法律法规。
公告由执行董事徐霆签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.